Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study

JAMA

Volumn 288, Issue 12, 2002, Pages 1475-1483

  Lyketsos, Constantine G ^a,f   Lopez, Oscar ^b   Jones, Beverly ^c   Fitzpatrick, Annette L ^d   Breitner, John ^e   Dekosky, Steven ^e  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; APATHY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE CLASSIFICATION; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; MULTICENTER STUDY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

EID: 0037174346     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.12.1475     Document Type: Article

References (62)

1. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
2. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)
3. Mild cognitive impairment represents early-stage Alzheimer disease
4. Behavioral and psychological signs and symptoms of dementia
5. Practice guideline for the treatment of patients with Alzheimer's diease and other dementias of late life
6. Psychosis and Alzheimer's disease
7. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease
8. National Institute of Mental Health: Provisional diagnostic criteria for depression of Alzheimer disease
9. Major and minor depression in Alzheimer's disease: Prevalence and impact
10. Predicting time to nursing home care and death in individuals with Alzheimer disease
11. Quality of life of patients with dementia in longterm care
12. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
13. The stress and psychological morbidity of the Alzheimer patient caregiver
14. Neuropsychiatric symptoms in dementia
15. Psychiatric phenomena in Alzheimer disease: Disorders of thought content
16. Psychiatric phenomena in Alzheimer disease: Disorders of perception
17. Psychiatric phenomena in Alzheimer disease: Disorders of mood
18. Psychiatric phenomena in Alzheimer disease: Disorders of behavior
19. Mental and neuropsychiatric symptoms in dementia: Findings from the Cache County Study on Memory in Aging
20. The Cardiovascular Health Study: Design and rationale
21. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study
22. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study
23. The Modified Mini-Mental State (3MS) Examination
24. The telephone interview for cognitive status
25. Assessment of cognitive decline in the elderly by informant interview
26. Magnetic resonance abnormalities and cardiovascular disease in older adults: The Cardiovascular Health Study
27. Evaluation of dementia in the Cardiovascular Health Cognition Study
28. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
29. A validation study of the Dementia Questionnaire
30. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group
31. Classification and prevalence of mild cognitive impairment in the Cardiovascular Health Study Cognition Study
32. Behavioral measures for cognitive disorders
33. NIMHCATIE: Alzheimer's disease clinical trial methodology
34. Mania in Alzheimer's disease
35. Wandering behavior in community-residing persons with dementia
36. SPECT study of delusions in Alzheimer disease
37. Neuropathologic and neurochemical correlates of psychosis in primary dementia
38. Neurochemical correlates of major depression in primary dementia
39. The neuropathology of aminergic nuclei in Alzheimer's disease
40. Clinical and neuropathological correlates of depression in Alzheimer's disease
41. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms
42. Physical aggression is associated with preservation of Substantia Nigra Pars Compacta in Alzheimer's disease
43. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease
44. Behavioral treatment of depression in dementia patients: A controlled clinical trial
45. Olanzapine in the treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities
46. Comparison of risperidone and placebo for psychosis and neuropsychiatric symptoms associated with dementia: A randomized, double-blind trial
47. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
48. A randomized, placebo controlled, dose comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
49. Randomized, placebo-controlled, double-blind, clinical trial of sertraline in the treatment of depression complicating Alzheimer disease: Initial results from the Depression in Alzheimer Disease Study
50. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
51. Moclobemide in elderly patients with cognitive decline and depression: An international double-blind, placebocontrolled trial
52. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
53. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
54. Placebo-controlled study of divalproex sodium for agitation in dementia
55. Low dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients
56. Cholinesterase inhibitors for Alzheimer's disease
57. A 5-month, randomized, placebo controlled trial of galantamine in AD
58. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review
59. The detection of dementia in the primary care setting